Corrigendum to "Mass spectrometry for therapeutic drug monitoring of anti-tuberculosis drugs" [Clin. Mass Spectrom. 14(Part A) (2019) 34-45].

MLA

Kuhlin, Johanna, et al. “Corrigendum to ‘Mass Spectrometry for Therapeutic Drug Monitoring of Anti-Tuberculosis Drugs’ [Clin. Mass Spectrom. 14(Part A) (2019) 34-45].” Journal of Mass Spectrometry and Advances in the Clinical Lab, vol. 25, Aug. 2022, p. 72. EBSCOhost, https://doi.org/10.1016/j.jmsacl.2022.08.001.

APA

Kuhlin, J., Sturkenboom, M. G. G., Ghimire, S., Margineanu, I., van den Elsen, S. H. J., Simbar, N., Akkerman, O. W., Jongedijk, E. M., Koster, R. A., Bruchfeld, J., Touw, D. J., & Alffenaar, J.-W. C. (2022). Corrigendum to “Mass spectrometry for therapeutic drug monitoring of anti-tuberculosis drugs” [Clin. Mass Spectrom. 14(Part A) (2019) 34-45]. Journal of Mass Spectrometry and Advances in the Clinical Lab, 25, 72. https://doi.org/10.1016/j.jmsacl.2022.08.001

Chicago

Kuhlin, Johanna, Marieke G G Sturkenboom, Samiksha Ghimire, Ioana Margineanu, Simone H J van den Elsen, Noviana Simbar, Onno W Akkerman, et al. 2022. “Corrigendum to ‘Mass Spectrometry for Therapeutic Drug Monitoring of Anti-Tuberculosis Drugs’ [Clin. Mass Spectrom. 14(Part A) (2019) 34-45].” Journal of Mass Spectrometry and Advances in the Clinical Lab 25 (August): 72. doi:10.1016/j.jmsacl.2022.08.001.